Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc (PHAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,010,871
  • Shares Outstanding, K 71,138
  • Annual Sales, $ 55,250 K
  • Annual Income, $ -334,330 K
  • EBIT $ -213 M
  • EBITDA $ -210 M
  • 60-Month Beta 0.43
  • Price/Sales 19.18
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 114.50% (-80.61%)
  • Historical Volatility 38.33%
  • IV Percentile 37%
  • IV Rank 13.73%
  • IV High 461.32% on 05/07/25
  • IV Low 59.29% on 08/20/25
  • Expected Move (DTE 8) 1.96 (13.44%)
  • Put/Call Vol Ratio 0.09
  • Today's Volume 126
  • Volume Avg (30-Day) 559
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 18,826
  • Open Int (30-Day) 23,211
  • Expected Range 12.60 to 16.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.21
  • Number of Estimates 1
  • High Estimate -0.21
  • Low Estimate -0.21
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +76.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.79 +5.51%
on 11/12/25
16.26 -10.54%
on 11/28/25
+0.82 (+5.97%)
since 11/10/25
3-Month
10.33 +40.85%
on 10/07/25
16.26 -10.54%
on 11/28/25
+2.23 (+18.10%)
since 09/10/25
52-Week
2.21 +558.37%
on 05/08/25
16.26 -10.54%
on 11/28/25
+5.62 (+62.93%)
since 12/10/24

Most Recent Stories

More News
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

First patient dosed, with topline results expected in 2027 pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04,...

PHAT : 14.55 (+2.39%)
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 14.55 (+2.39%)
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Over 790,000 total VOQUEZNA® prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating...

PHAT : 14.55 (+2.39%)
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically...

PHAT : 14.55 (+2.39%)
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 14.55 (+2.39%)
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical...

PHAT : 14.55 (+2.39%)
Cantor Fitzgerald Sticks to Its Buy Rating for Phathom Pharmaceuticals (PHAT)

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Phathom Pharmaceuticals today and set a price target of $29.00. The company’s shares opened today at $12.62.Elevate Your Investing...

PHAT : 14.55 (+2.39%)
Craig-Hallum Remains a Buy on Phathom Pharmaceuticals (PHAT)

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Phathom Pharmaceuticals. The company’s shares closed last Friday at $11.82.Elevate Your Investing Strategy:...

PHAT : 14.55 (+2.39%)
Cantor Fitzgerald Sticks to Their Buy Rating for Phathom Pharmaceuticals (PHAT)

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Phathom Pharmaceuticals yesterday and set a price target of $29.00. The company’s shares closed yesterday at $11.05.Elevate Your Investing...

PHAT : 14.55 (+2.39%)
Phathom Pharmaceuticals Appoints New Chief Financial Officer

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Phathom Pharmaceuticals...

PHAT : 14.55 (+2.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo...

See More

Key Turning Points

3rd Resistance Point 15.27
2nd Resistance Point 14.95
1st Resistance Point 14.75
Last Price 14.55
1st Support Level 14.23
2nd Support Level 13.92
3rd Support Level 13.72

See More

52-Week High 16.26
Last Price 14.55
Fibonacci 61.8% 10.90
Fibonacci 50% 9.24
Fibonacci 38.2% 7.58
52-Week Low 2.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar